Paul Saenger
Overview
Explore the profile of Paul Saenger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
711
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grillo M, Frank J, Saenger P
Front Pediatr
. 2023 Oct;
11:1254231.
PMID: 37842029
In 1957, Maurice Raben at Yale was able to isolate and purify growth hormone from cadaveric pituitary glands. Pituitary growth hormone was the only way to treat children with growth...
2.
Savendahl L, Battelino T, Rasmussen M, Brod M, Rohrich S, Saenger P, et al.
J Clin Endocrinol Metab
. 2023 Mar;
108(10):2569-2578.
PMID: 36995872
Context: Growth hormone deficiency (GHD) in children is currently treated with daily injections of GH, which can be burdensome for patients and their parents/guardians. Somapacitan is a GH derivative in...
3.
Steiner M, Frank J, Saenger P
Pediatr Investig
. 2023 Mar;
7(1):36-42.
PMID: 36967745
After the isolation of pituitary growth hormone (GH) in 1957, this form of GH, always in limited supply, was the only drug available for the treatment of GH deficiency. In...
4.
Steiner M, Saenger P
Adv Pediatr
. 2022 Aug;
69(1):177-202.
PMID: 35985709
Turner syndrome is the most common sex chromosome abnormality in women. Infertility and short stature are the most striking findings seen in these patients. Unfortunately, many girls are still being...
5.
Maniatis A, Casella S, Nadgir U, Hofman P, Saenger P, Chertock E, et al.
J Clin Endocrinol Metab
. 2022 Apr;
107(7):e2680-e2689.
PMID: 35428884
Purpose: The objectives of the ongoing, Phase 3, open-label extension trial enliGHten are to assess the long-term safety and efficacy of weekly administered long-acting growth hormone lonapegsomatropin in children with...
6.
Maniatis A, Nadgir U, Saenger P, Reifschneider K, Abuzzahab J, Deeb L, et al.
Horm Res Paediatr
. 2022 Mar;
95(3):233-243.
PMID: 35263755
Introduction: The phase 3 fliGHt Trial evaluated the safety and tolerability of once-weekly lonapegsomatropin, a long-acting prodrug, in children with growth hormone deficiency (GHD) who switched from daily somatropin therapy...
7.
Savendahl L, Battelino T, Rasmussen M, Brod M, Saenger P, Horikawa R
J Clin Endocrinol Metab
. 2021 Dec;
107(5):1357-1367.
PMID: 34964458
Context: Current GH therapy requires daily injections, which can be burdensome. Somapacitan is a long-acting GH derivative in development for treatment of GH deficiency (GHD). Objective: Evaluate the efficacy, safety,...
8.
Saenger P, Steiner M
Pediatr Investig
. 2021 Dec;
5(4):323-324.
PMID: 34938976
No abstract available.
9.
Savendahl L, Battelino T, Brod M, Rasmussen M, Kildemoes R, Saenger P
J Clin Endocrinol Metab
. 2021 Oct;
107(2):e888-e889.
PMID: 34626473
No abstract available.
10.